These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 38548444)

  • 1. Preventing Readmissions for Hepatic Encephalopathy.
    Makhani SS; Lee S; Bernstein D
    Clin Liver Dis; 2024 May; 28(2):345-358. PubMed ID: 38548444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preventing Readmissions of Hepatic Encephalopathy: Strategies in the Acute Inpatient, Immediate Postdischarge, and Longitudinal Outpatient Setting.
    Lin E; Gandhi D; Volk M
    Clin Liver Dis; 2024 May; 28(2):359-367. PubMed ID: 38548445
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-Effectiveness of Rifaximin Treatment in Patients with Hepatic Encephalopathy.
    Jesudian AB; Ahmad M; Bozkaya D; Migliaccio-Walle K
    J Manag Care Spec Pharm; 2020 Jun; 26(6):750-757. PubMed ID: 32463782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatic Encephalopathy-Related Hospitalizations in Cirrhosis: Transition of Care and Closing the Revolving Door.
    Frenette CT; Levy C; Saab S
    Dig Dis Sci; 2022 Jun; 67(6):1994-2004. PubMed ID: 34169435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thirty-Day Readmissions Are Largely Not Preventable in Patients With Cirrhosis.
    Orman ES; Desai AP; Ghabril MS; Nephew LD; Patidar KR; Holden J; Samala NR; Gawrieh S; Vuppalanchi R; Sozio M; Lacerda M; Vilar-Gomez E; Lammert C; Liangpunsakul S; Crabb D; Masuoka H; Dakhoul L; Pan M; Gao S; Chalasani N
    Am J Gastroenterol; 2024 Feb; 119(2):287-296. PubMed ID: 37543729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatic encephalopathy and strategies to prevent readmission from inadequate transitions of care.
    Rosenstengle C; Kripalani S; Rahimi RS
    J Hosp Med; 2022 Aug; 17 Suppl 1():S17-S23. PubMed ID: 35972038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-Term Management: Modern Measures to Prevent Readmission in Patients with Hepatic Encephalopathy.
    Rosenblatt R; Yeh J; Gaglio PJ
    Clin Liver Dis; 2020 May; 24(2):277-290. PubMed ID: 32245533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current approach to treatment of minimal hepatic encephalopathy in patients with liver cirrhosis.
    Moran S; López-Sánchez M; Milke-García MDP; Rodríguez-Leal G
    World J Gastroenterol; 2021 Jun; 27(22):3050-3063. PubMed ID: 34168407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes after hepatic encephalopathy in population-based cohorts of patients with cirrhosis.
    Tapper EB; Aberasturi D; Zhao Z; Hsu CY; Parikh ND
    Aliment Pharmacol Ther; 2020 Jun; 51(12):1397-1405. PubMed ID: 32363684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An Electronic Decision Support Intervention Reduces Readmissions for Patients With Cirrhosis.
    Louissaint J; Grzyb K; Bashaw L; Mohammad RA; Parikh ND; Tapper EB
    Am J Gastroenterol; 2022 Mar; 117(3):491-494. PubMed ID: 35020619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatic Encephalopathy: Diagnosis and Treatment in Advanced Liver Disease.
    Reed V
    Crit Care Nurs Clin North Am; 2022 Sep; 34(3):331-339. PubMed ID: 36049852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hospital readmissions in decompensated cirrhotics: Factors pointing toward a prevention strategy.
    Seraj SM; Campbell EJ; Argyropoulos SK; Wegermann K; Chung RT; Richter JM
    World J Gastroenterol; 2017 Oct; 23(37):6868-6876. PubMed ID: 29085229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of once a day rifaximin to twice a day dosage in the prevention of recurrence of hepatic encephalopathy in patients with chronic liver disease.
    Khokhar N; Qureshi MO; Ahmad S; Ahmad A; Khan HH; Shafqat F; Salih M
    J Gastroenterol Hepatol; 2015 Sep; 30(9):1420-2. PubMed ID: 25867912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Health Care Burden of Hepatic Encephalopathy.
    Harris KB; Gonzalez HC; Gordon SC
    Clin Liver Dis; 2024 May; 28(2):265-272. PubMed ID: 38548438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of hepatic encephalopathy in patients with cirrhosis treated with current standards of care.
    Bohra A; Worland T; Hui S; Terbah R; Farrell A; Robertson M
    World J Gastroenterol; 2020 May; 26(18):2221-2231. PubMed ID: 32476788
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Health Care Burden of Hepatic Encephalopathy.
    Elsaid MI; John T; Li Y; Pentakota SR; Rustgi VK
    Clin Liver Dis; 2020 May; 24(2):263-275. PubMed ID: 32245532
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rates of and Reasons for Hospital Readmissions in Patients With Cirrhosis: A Multistate Population-based Cohort Study.
    Tapper EB; Halbert B; Mellinger J
    Clin Gastroenterol Hepatol; 2016 Aug; 14(8):1181-1188.e2. PubMed ID: 27085758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targets to improve quality of care for patients with hepatic encephalopathy: data from a multi-centre cohort.
    Bajaj JS; O'Leary JG; Tandon P; Wong F; Kamath PS; Biggins SW; Garcia-Tsao G; Lai J; Fallon MB; Thuluvath PJ; Vargas HE; Maliakkal B; Subramanian RM; Thacker LR; Reddy KR
    Aliment Pharmacol Ther; 2019 Jun; 49(12):1518-1527. PubMed ID: 31032966
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatic Encephalopathy in Children.
    Bartlett JA; Kohli R
    Indian J Pediatr; 2024 Mar; 91(3):280-285. PubMed ID: 37310582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of rifaximin on the hospital burden and infections in patients with hepatic encephalopathy: a retrospective observational study.
    De Graeve J; Vanderstraeten E; Delvaeye T; De Lepeleere S; De Somer T; Van Steenkiste C
    Acta Gastroenterol Belg; 2022; 85(3):433-437. PubMed ID: 35833904
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.